Advantages and limitations of amino acid PET for tracking therapy response in glioma patients

Karl-Josef Langen*, Alexander Heinzel, Philipp Lohmann, Felix M. Mottaghy, Norbert Galldiks

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

Original languageEnglish
Pages (from-to)137-146
Number of pages10
JournalExpert Review of Neurotherapeutics
Volume20
Issue number2
DOIs
Publication statusPublished - 1 Feb 2020

Keywords

  • Cerebral glioma
  • PET
  • radiolabeled amino acids
  • treatment monitoring
  • POSITRON-EMISSION-TOMOGRAPHY
  • RECURRENT MALIGNANT GLIOMA
  • HIGH-GRADE GLIOMAS
  • O-(2-F-18-FLUOROETHYL)-L-TYROSINE PET
  • TEMOZOLOMIDE CHEMOTHERAPY
  • EUROPEAN ASSOCIATION
  • F-DOPA
  • BRAIN
  • BEVACIZUMAB
  • TUMOR

Cite this